Susquehanna International Group’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
Sell
-186,083
Closed -$101K 10725
2016
Q3
$101K Sell
186,083
-176,169
-49% -$80.5K ﹤0.01% 7939
2016
Q2
$211K Buy
362,252
+13,980
+4% +$14.9K ﹤0.01% 7531
2016
Q1
$508K Buy
348,272
+121,286
+53% +$239K ﹤0.01% 6371
2015
Q4
$726K Sell
226,986
-534,714
-70% -$2.57M ﹤0.01% 6061
2015
Q3
$4.76M Buy
761,700
+81,404
+12% +$761K ﹤0.01% 2739
2015
Q2
$6.75M Buy
680,296
+451,209
+197% +$3.95M ﹤0.01% 2495
2015
Q1
$1.69M Buy
229,087
+144,213
+170% +$970K ﹤0.01% 4646
2014
Q4
$454K Sell
84,874
-173,582
-67% -$888K ﹤0.01% 7409
2014
Q3
$1.3M Sell
258,456
-4,168
-2% -$25.6K ﹤0.01% 5418
2014
Q2
$1.76M Buy
262,624
+50,144
+24% +$319K ﹤0.01% 4898
2014
Q1
$1.54M Buy
212,480
+140,805
+196% +$835K ﹤0.01% 4756
2013
Q4
$270K Buy
+71,675
New +$277K ﹤0.01% 7761

Other funds holding NWBO

Susquehanna International Group's NWBO Position: Q4 2016 in Review

Susquehanna International Group sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 186,083 shares — an estimated $101K sold.

Susquehanna International Group first reported a position in NWBO in Q4 2013 and held it in 12 quarters. The position peaked at $6.75M in Q2 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • Susquehanna International Group reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • Susquehanna International Group sold 186,083 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $101K.
  • Susquehanna International Group first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2013 and held it in 12 quarters.
  • Susquehanna International Group's Northwest Biotherapeutics, Inc. Common stock position peaked at $6.75M in Q2 2015.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Susquehanna International Group's 13F filing for Q4 2016, filed 14 Feb 2017.